DNA METHYLATION AGE ACROSS PREGNANCY

Racial Differences in DNA Methylation-Based Age Acceleration in Preeclamptic and Normotensive Pregnancy

Lacey W. Heinsberg, PhD, RN¹⁻³; Mitali Ray, PhD, RN⁴; Yvette P. Conley, PhD, FAAN^{1,4}; James M. Roberts, MD^{3,5-8}; Arun Jeyabalan, MD^{3,5,6,8}; Carl A. Hubel, PhD^{5,6}; Daniel E. Weeks, PhD^{1,9}; Mandy J. Schmella, PhD, RN⁴

¹ Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh; Pittsburgh, Pennsylvania, USA

² Division of Internal Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

³ Clinical and Translational Science Institute; University of Pittsburgh, Pittsburgh, Pennsylvania, USA

⁴ Department of Health Promotion and Development, School of Nursing, University of Pittsburgh; Pittsburgh, Pennsylvania, USA

⁵ Department of Obstetrics, Gynecology, & Reproductive Sciences, School of Medicine, University of Pittsburgh, Pennsylvania, USA

⁶ Magee-Womens Research Institute; Pittsburgh, Pennsylvania, USA

⁷ Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh; Pittsburgh, Pennsylvania, USA

⁸ Global Pregnancy Collaboration

⁹ Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh; Pittsburgh, Pennsylvania, USA

Corresponding author: Lacey W. Heinsberg, PhD, RN
Department of Human Genetics
Graduate School of Public Health
University of Pittsburgh
130 De Soto Street
Pittsburgh, PA 15261
E-mail: law145@pitt.edu

DNA METHYLATION AGE ACROSS PREGNANCY

ABSTRACT

Background: Preeclampsia is a leading cause of maternal and neonatal morbidity and mortality. Chronological age and race are associated with increased risk of preeclampsia; however, the pathophysiology of preeclampsia and how these risk factors impact its development, are not entirely understood. This gap precludes clinical interventions to prevent preeclampsia occurrence or to address stark racial disparities in maternal and neonatal outcomes. Of note, cellular aging rates can differ between individuals and chronological age is often a poor surrogate of biological age. DNA methylation age provides a marker of biological aging, and those with a DNA methylation age greater than their chronological age have ‘age acceleration’. Examining age acceleration in the context of preeclampsia status, and race, could strengthen our understanding of preeclampsia pathophysiology, inform future interventions to improve maternal/neonatal outcomes, and provide insight to racial disparities across pregnancy. **Objectives:** The purpose of this exploratory study was to examine associations between age acceleration, preeclampsia status, and race across pregnancy. **Study design:** This was a longitudinal, observational, case-control study of 56 pregnant individuals who developed preeclampsia (n=28) or were normotensive controls (n=28). Peripheral blood samples were collected at trimester-specific time points and genome-wide DNA methylation data were generated using the Infinium MethylationEPIC Beadchip. DNA methylation age was estimated using the Elastic Net ‘Improved Precision’ clock and age acceleration was computed as Δage , the difference between DNA methylation age and chronological age. DNA methylation age was compared with chronological age using scatterplots and Pearson correlations, while considering preeclampsia status and race. The relationships between preeclampsia status, race, and Δage were formally tested using multiple linear regression, while adjusting for pre-pregnancy body mass index, chronological age, and $(\text{chronological age})^2$. Regressions were performed both with and without consideration of cell-type heterogeneity. **Results:** We observed strong correlations between chronological age and DNA methylation age in all trimesters, ranging from $R=0.91-0.95$ in cases and $R=0.86-0.90$ in controls. We observed significantly stronger correlations between chronological age and DNA methylation age in White versus Black participants ranging from $R=0.89-0.98$ in White participants and $R=0.77-0.83$ in Black participants. We observed no association between Δage and preeclampsia status within trimesters. However, even while controlling for covariates, Δage was higher in trimester 1 in participants with higher pre-

DNA METHYLATION AGE ACROSS PREGNANCY

pregnancy BMI ($\beta=0.12$, 95% CI=0.02 to 0.22, $p=0.02$) and lower in Black participants relative to White participants in trimesters 2 ($\beta=-2.68$, 95% CI=-4.43 to -0.94, $p=0.003$) and 3 ($\beta=-2.10$, 95% CI=-4.03 to -0.17, $p=0.03$). When controlling for cell-type heterogeneity, the observations with BMI in trimester 1 and race in trimester 2 persisted. **Conclusions:** We report no association between Δage and preeclampsia status, although there were associations with pre-pregnancy BMI and race. In particular, our findings in a small sample demonstrate the need for additional studies to not only investigate the complex pathophysiology of preeclampsia, but also the relationship between race and biological aging, which could provide further insight into racial disparities in pregnancy and birth. Future efforts to confirm these findings in larger samples, including exploration and applications of other epigenetic clocks, is needed.

Keywords: Biologic aging; epigenetic age; epigenetics; hypertensive disorders of pregnancy; maternal health; methylation; pre-eclampsia; pregnancy; race; racial disparities.

DNA METHYLATION AGE ACROSS PREGNANCY

INTRODUCTION

While the majority of developed nations have low and declining maternal mortality rates, the United States serves as a striking exception.¹ Preeclampsia (PE) is a leading cause of maternal morbidity/mortality, affecting 4.6% of pregnancies globally.^{2,3} In addition to severe, and often life-threatening complications during pregnancy and delivery, those who develop PE are at higher risk of long-term health complications, including hypertension, myocardial infarction, and stroke.^{4,5} Marked racial disparities exist in maternal morbidity/mortality,^{6,7} with both the prevalence of PE and the maternal mortality rate being higher among Black individuals relative to White individuals.^{6,7} Racial disparities in poverty, stress, and early prenatal care exist even when adjusting for demographic differences.⁸⁻¹⁰ As such, there is a critical need for studies that address the underlying biological mechanisms that contribute to racial differences observed in PE.

In addition to race, individuals in the youngest and highest chronological age groups have a higher risk of PE, although the biology and pathophysiology behind this is not completely understood.¹¹ Because of variability in environmental, social, and genomic factors, it is thought that ‘biological aging’ may happen at different rates than chronological aging between individuals, and that chronological age is a poor surrogate for this phenomenon.¹² Methods to estimate biological age based on DNA methylation (DNAm) have been developed and termed ‘epigenetic clocks’.¹³⁻¹⁵ Individuals with a DNAm age greater than their chronological age are said to have ‘age acceleration,’ which is associated with various adverse health outcomes, including cancers, cardiovascular disease, and death.^{13,14,16} Because age acceleration represents a biological metric, investigating the relationship between age acceleration and PE status may provide valuable insight into the biologic perturbations associated with PE and race, and inform future interventions to improve maternal and neonatal outcomes. Therefore, the purpose of this exploratory study was to examine associations between age acceleration, PE status, and race across pregnancy.

MATERIALS AND METHODS

Study design, setting, and sample

This was an exploratory, case-control study of pregnant individuals who developed PE and normotensive controls that capitalized on existing phenotype data and stored bio-specimens that were collected as part of a larger prospective, longitudinal study of pregnancy and PE risk

DNA METHYLATION AGE ACROSS PREGNANCY

factors focused on obesity (NICHD-P01HD30367). Informed consent was obtained, and participants were prospectively recruited from UPMC Magee-Womens Hospital (2008-2014) at their first prenatal appointment if they were 14-40 years of age, had a singleton pregnancy, and had no past medical history of conditions associated with an increased risk of PE (e.g., chronic hypertension, diabetes).⁵ Participants were followed across pregnancy, and demographic, clinical, and social characteristic data and bio-specimens were collected.

A subset of 56 participants (28 PE cases and 28 normotensive controls) were selected for inclusion in the current study if they had DNA samples available for all three trimesters of pregnancy and were able to be frequency matched to a case or control based on race, pre-pregnancy body mass index (BMI), smoking status, and gestational age at sample collection. Study protocols were approved by the University of Pittsburgh Institutional Review Board, and we have adhered to all ethical considerations in the treatment of participants.

Participant characteristics

Pregnancy outcome (PE status)

Pregnancy outcome, discussed here as PE status (i.e., cases versus controls), was based on a review of clinical data and juried chart review by an expert panel of clinicians/researchers. Case status (PE+) was classified as the co-occurrence of new-onset gestational hypertension and proteinuria after 20 weeks' gestation in previously normotensive participants. Gestational hypertension was determined as the average of the last four in-hospital blood pressure measurements taken prior to administration of medication that might impact blood pressure. Gestational hypertension was defined as a systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg that returned to baseline by 12 weeks postpartum. Proteinuria was a urinary protein excretion rate ≥ 300 mg/24 hours, protein/creatinine ratio ≥ 0.3 , $\geq 2+$ on a random urine specimen, or $\geq 1+$ on a catheterized urine specimen. Control status (PE-) was classified as normotensive throughout gestation, negative for proteinuria, and an uncomplicated pregnancy outcome.

Demographic, clinical, and household factors

Participant- and household-level factors were self-reported by participants in survey data, and included maternal age, race, pre-pregnancy height/weight, smoking history (>100 lifetime cigarettes, yes/no), marital/relationship status, education level, household income, and receipt of public assistance. Clinical data were extracted from maternal and infant medical records and

DNA METHYLATION AGE ACROSS PREGNANCY

included pregnancy and labor/delivery information.

DNA methylation data

Peripheral blood samples were collected at trimester-specific time points (Table 1). DNA was extracted from blood samples using protein precipitation¹⁷ and stored in 1X TE buffer at -40°C following DNA extraction. DNA was bisulfite converted, and genome-wide DNAm data were collected using the Infinium MethylationEPIC Beadchip (Illumina, San Diego, CA, USA). Detailed information on chip design, data cleaning, and quality control procedures are provided in the Supplementary Material (Section S.1.1). Our final data set consisted of 703,200 probes in 56 participants at up to three trimester-specific time points.

Cell-type heterogeneity, DNA methylation age, and Δage

Cell-type heterogeneity data were generated from the genome-wide DNAm data using Houseman's reference-based method¹⁸ as previously described¹⁹ and detailed in the Supplementary Material (Section S.1.2). DNAm age was estimated from the genome-wide DNAm data using the Elastic Net 'Improved Precision' epigenetic clock discussed in the Supplementary Material (Section S.1.3).¹⁵ Using publicly available sourcecode,²⁰ we estimated DNAm age through linear functions by applying clock-specific probes and coefficients.¹⁵ Details of the probes, coefficients, and data missingness are presented (Table S1). Age acceleration was computed as Δage , the difference between DNAm age and chronological age (Equation S1). The rationale for using Δage included its clinical relevance to the study goals as discussed in detail in the Supplementary Material (Section S.1.4).

Statistical analysis

All statistical analyses were performed in R version 3.6.0.²¹ Standard descriptive statistics were computed, and data were examined graphically and statistically for missingness, outliers, and assumptions of linear regression. Preliminary analyses were conducted to identify potential covariates/confounders and included group comparisons to evaluate equality of means or group proportions based on variable type. DNAm age was compared with chronological age using scatterplots and Pearson correlation coefficients while considering PE status and race, and regression lines were drawn to better understand this relationship relative to $y=x$. Group differences between correlations by PE status and race were formally tested using Fisher Z-transformation. The distribution of Δage was examined using *sina* and *spaghetti* plots.

To examine the relationship between Δage and participant characteristics, we applied

DNA METHYLATION AGE ACROSS PREGNANCY

multiple linear regression while adjusting for covariates identified in our preliminary analyses. Model assessment was performed using residual analysis and influence diagnostics. Unstandardized regression estimates (β), 95% confidence intervals (CI), and p-values for each regression coefficient were obtained. R^2 values were reported as the percent of variation in Δage explained by each model and p-values <0.05 were considered significant. To explore the influence of cell-type heterogeneity on Δage , we first used principal component analysis to reduce the dimensionality of our cell-type heterogeneity data to stabilize regression parameters in our small sample size as described in the Supplementary Material (Section S.1.5). Regression analyses were repeated while controlling for the principal components accounting for $>90\%$ of cumulative proportion of variance in the cell-type heterogeneity data.²²

RESULTS

Sample characteristics

Participant characteristics by both PE status, and self-reported race (Black/White) ignoring PE status, are presented (Table 1). The overall sample had a mean chronological age ($\pm$ SD) of 23.8 ($\pm$ 4.6) years and mean BMI of 33.3 ($\pm$ 7.4) kg/m². Further, 75% self-reported their race as Black, 66.0% reported no history of smoking, and 67.9% reported never being married. Mean gestational age at sample collection in trimesters 1, 2, and 3 were 8.8 ($\pm$ 1.6), 19.7 ($\pm$ 1.3), and 37.2 ($\pm$ 2.5) weeks, respectively, and 80.4% of the sample was nulliparous. With respect to blood pressure, we observed a suggestive difference in diastolic blood pressure at <20 weeks' gestation by PE status ($p=0.05$). As expected, statistically significant differences by PE status were observed later in pregnancy, as PE cases had significantly higher blood pressures upon hospital admission for delivery (systolic, $p=2.2E-16$; diastolic, $p=1.1E-13$), delivered at an earlier gestation ($p=0.0002$), and delivered smaller infants ($p=0.001$) relative to controls.

When comparing participant characteristics by race, several statistically significant differences were observed (Table 1). Specifically, in Black participants versus White participants, we observed younger mean chronological age ($p=0.0007$), a higher proportion of participants who reported never being married ($p=0.0005$), fewer years of education ($p=0.02$), lower annual household income ($p=0.001$), lower systolic blood pressure before 20 weeks' gestation ($p=0.004$), and a trend towards lower pre-pregnancy BMI ($p=0.06$).

DNA METHYLATION AGE ACROSS PREGNANCY

DNA methylation age and Δage

We observed strong correlations between chronological age and DNAm age in all trimesters with slightly, but not significantly, stronger correlations in cases than in controls (Figure 1A). Correlations ranged from $R=0.91$ - 0.95 in cases and $R=0.86$ - 0.90 in controls. We also observed stronger correlations between chronological age and DNAm age in White versus Black participants (Figure 1B), with statistically significant differences by race observed in Trimester 2 ($p=0.0008$) and 3 ($p=0.002$). Correlations ranged from $R=0.89$ - 0.98 in White participants and $R=0.77$ - 0.83 in Black participants.

Figure 1. Trimester-specific comparison of chronological age and DNA methylation age by PE status and self-reported race.

Trimester-specific comparison of chronological age versus DNA methylation age by (A) PE status and (B) self-reported race; R, Pearson correlation coefficient; black dashed line, $y=x$; solid lines, regression lines fitted to the data by PE status or self-reported race as depicted in legends.

The distribution of Δage by trimester, PE status, and race is presented in the Supplementary Material (Figure S3). We observed generally smaller Δage values, but with greater variability, in Black participants versus White participants and no apparent difference by PE status within trimesters. Finally, trajectories of Δage over time by PE status and race are presented (Figure 2) with no apparent differences by PE status. However, Δage appeared generally lower in Black participants versus White participants.

DNA METHYLATION AGE ACROSS PREGNANCY

Figure 2. Δage over time by PE status and self-reported race.

Spaghetti plot of Δage over time by (A) PE status and (B) self-reported race; Δage = DNA methylation age – chronological age (Equation S1).

Participant characteristics and Δage

Multiple linear regression was used to formally test the relationships between PE status and Δage while controlling for covariates (Table 2). In bivariate analyses, we observed associations between Δage and race in trimesters 1, 2, and 3 ($p=0.01$, $p=6.16e-5$, and $p=0.002$, respectively) and pre-pregnancy BMI in trimester 1 ($p=0.003$). Because of the systematic difference in Δage by chronological age reported elsewhere²³ and observed to a small degree in our data (Figure S4), we adjusted for chronological age and (chronological age)² in our regression as discussed in the Supplementary Material (Section S.1.4).^{24–26} Given our small sample size, covariates were limited to PE status, race, chronological age, (chronological age)², and pre-pregnancy BMI.

In regressing Δage on these factors, we observed no association with PE status in trimester 1, 2, or 3. However, we observed an association with pre-pregnancy BMI in trimester 1 ($\beta=0.12$, 95% CI=0.02 to 0.22, $p=0.02$), and race in trimester 2 ($\beta=-2.68$, 95% CI=-4.43 to -0.94, $p=0.003$) and trimester 3 ($\beta=-2.10$, 95% CI=-4.03 to -0.17, $p=0.03$) (Table 2A and Figure S5). We repeated our analyses controlling for cell-type heterogeneity principal components; the associations with pre-pregnancy BMI in trimester 1 ($\beta=0.12$, 95% CI=0.02 to 0.22, $p=0.02$) and race in trimester 2 ($\beta=-2.68$, 95% CI=-4.43 to -0.94, $p=0.003$) persisted (Table 2B).

DNA METHYLATION AGE ACROSS PREGNANCY

DISCUSSION

Summary of main findings

Even while controlling for covariates, Δage was higher in trimester 1 in participants with higher pre-pregnancy BMI and lower in trimesters 2 and 3 in Black participants relative to White participants. When controlling for cell-type heterogeneity, the observations with BMI in trimester 1 and race in trimester 2 persisted. We observed no association between Δage and PE status within trimesters. Beyond the formal analysis to identify factors associated with Δage , there were striking differences in the correlation between chronological age and DNAm age by race, particularly in trimesters 2 and 3, with stronger correlation in White individuals relative to Black individuals.

Comparison with existing literature

There are several noteworthy studies relevant to our work, though important differences in the choice of tissue, consideration of race, sample studied, and specific epigenetic clocks and age acceleration metrics applied make direct comparison challenging. Specifically, researchers recently developed an epigenetic clock to predict the gestational age of placentas and identified an association between accelerated placental aging and early onset PE.²⁷ While these data may inform PE pathophysiology, access to placenta is only available post-birth, making it less relevant when seeking a non-invasive predictor of PE. Moreover, we could not apply the placental aging clock to our DNAm data generated from blood because DNAm is tissue-specific.

To our knowledge, no additional literature evaluating epigenetic aging in PE exists. However, in a study of normotensive pregnancy, age acceleration computed using a variety of metrics was found to decrease from pregnancy to the postpartum period.²⁸ Although the authors mentioned race-specific differences in DNAm age, the direction of effect was not provided.²⁸ In the same study, however, BMI at one year post-delivery reflecting pregnancy-related weight retention was associated with increased age acceleration computed using extrinsic epigenetic age, which controls for aging-related shifts in immune-related cell-type heterogeneity.²⁸ We did not have BMI and DNAm data post-delivery for comparison, but we did observe a similar association between higher pre-pregnancy BMI and higher Δage in trimester 1, even while controlling for cell-type heterogeneity, further supporting the role of BMI in biological aging. In a related study of normotensive pregnancy, higher maternal age acceleration computed using a variety of metrics was associated with infant outcomes including shorter infant length and lower

DNA METHYLATION AGE ACROSS PREGNANCY

birthweight.²⁹ *Post hoc* analyses revealed no association between Δage and infant birth weight in our study, though this relationship is likely confounded in our small sample size by low gestational age at delivery for infants of PE pregnancies.

For DNAm aging and racial differences specifically, our observation of lower Δage of Black individuals relative to White individuals is consistent with literature showing both longer leukocyte telomere length^{30,31} and lower age acceleration³² in Black individuals relative to White individuals. Observations of Black individuals appearing ‘biologically younger’ presents a paradox as Black individuals have higher disease incidence, lower average life expectancies, and generally greater inflammation.³²

Clinical and research implications

Our observations suggest that higher pre-pregnancy BMI may lead to higher biological burden relative to cellular aging. This finding is supported by existing literature in both pregnant and non-pregnant individuals,^{28,33,34} and may provide insight into age-related disease outcomes. Because it is as a modifiable factor, BMI represents an important clinical target to improve outcomes. In addition, we observed smaller Δage in Black participants relative to White participants even when controlling for chronological age, pre-pregnancy BMI, PE status, and cell-type heterogeneity. Additional work is needed to understand this observation before it can offer clinical utility. We observed no difference in Δage by PE status, limiting the potential utility of DNAm age as a clinical screening tool for PE.

The lack of association between Δage by PE status is surprising because of immunological/inflammatory underpinnings of PE,³⁵ which we anticipated might influence DNAm age. Notably, the ‘Improved Precision’ clock was developed with training data from >12,000 samples and created a ‘near perfect’ predictor of chronological age.¹⁵ The authors argue that training data of this size may mask inter-individual variation in biological age, and associations with all-cause mortality in other clocks may be a product of smaller training data and greater variation.¹⁵ Moreover, the ‘Improved Precision’ clock was designed to be less dependent on cell-type heterogeneity;¹⁵ this is supported by our results (Table 2 and Figure S6) but may mask an association with PE status. Unfortunately, we were unable to compare the ‘Improved Precision’ clock with more established clocks^{13,14,16} due to the proportion of clock-specific probes missing from the data. Future PE research should explore the utility of other clocks in larger samples.

DNA METHYLATION AGE ACROSS PREGNANCY

Although the observation of lower Δage in Black individuals relative to White individuals is consistent with existing literature in pregnant and non-pregnant individuals^{28,32}, it is possible that this observation could be confounded by the choice of training data used to develop existing epigenetic clocks. Because White individuals are more likely to be included in research studies than other races or ethnicities³⁶, the majority of publicly available training data from which to develop epigenetic clocks is, by nature, from White individuals. The ‘Improved Precision’ clock applied here was no exception, though the authors argue that because their training sample was so large it is less influenced by cell-type heterogeneity¹⁵ that can vary by race.^{19,37} While more established methods were developed based on training data from mixed populations^{13,14}, the majority of training samples were from White individuals. The concept of race-specific age estimators should be explored for comparison.

Strengths/limitations

Unique strengths of this study include our longitudinal approach to characterize DNAm age across pregnancy, focus on biological racial differences, and rigorous case-control matching that resulted in only expected differences by participant phenotype. However, this careful matching limited the generalizability of the results. Our sample was skewed towards the obese given the larger study’s focus on pregnancy complications associated with BMI. Also, our control criteria were quite stringent, perhaps identifying ‘supra-normal’ controls. Future work in more generalized samples is necessary.

Despite rigorous participant selection, cases and controls were not matched on maternal age. Although no differences in chronological age were noted by PE status, Black participants had a significantly lower mean chronological age than White participants (22.2 and 28.4 years, respectively). We controlled for the systematic difference in Δage by chronological age²³ and the results between Δage and race persisted. Similarly, while cases/controls were matched on pre-pregnancy BMI, White participants were more obese than Black participants, which resulted in a suggestive difference in BMI by race. Nevertheless, we controlled for BMI in our analyses and the racial differences persisted. Our small sample size prevented us from controlling for additional variables that could influence our results (e.g., preterm versus term PE, gestational diabetes). Paired with the substantial clinical heterogeneity in PE presentation, severity, and outcomes, the distinct pathophysiological mechanisms at play may be buried and confound our results. Future work exploring these factors in larger sample sizes is needed.

DNA METHYLATION AGE ACROSS PREGNANCY

Conclusions

We report no association between Δage and PE status but did observe higher Δage in trimester 1 in participants with higher pre-pregnancy BMI and lower Δage in trimesters 2 and 3 in Black participants relative to White participants. Future applications of other epigenetic clocks should confirm these findings by PE status and examine the observation that Black individuals appeared ‘biologically younger’ than White individuals later in pregnancy. Sustained efforts to resolve racial health disparities should include examination of biological, environmental, and social determinants of health.

Ethical Approval: This study has Institutional Review Board Approval from the University of Pittsburgh.

Data availability: dbGAP, accession number: phs001937.v1.p1

Sources of funding: Research reported in this publication was supported by the National Institute of Child Health and Human Development (R21HD092770 and P01HD303067), National Center for Advancing Translational Sciences (TL1TR001858), and National Institute of Nursing Research (T32NR009759) of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of Interest: The funders had no role in the design of the study; collection, analyses, or interpretation of data; writing of the manuscript; or decision to publish the results. As such, the authors declare no conflict of interest.

Acknowledgements: We would like to thank the participants for their involvement in this research and Sandra Deslouches, Laboratory Manager at the University of Pittsburgh School of Nursing, for her expertise and assistance in sample preparation.

DNA METHYLATION AGE ACROSS PREGNANCY

REFERENCES

1. Geller SE, Koch AR, Garland CE, MacDonald EJ, Storey F, Lawton B. A global view of severe maternal morbidity: Moving beyond maternal mortality. *Reprod Health*. 2018;15(Suppl 1). doi:10.1186/s12978-018-0527-2.
2. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for Preeclampsia US preventive services task force recommendation statement. *JAMA - J Am Med Assoc*. 2017;317(16):1661-1667. doi:10.1001/jama.2017.3439.
3. Ananth C V, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: Age-period-cohort analysis. *BMJ*. 2013;347. doi:10.1136/bmj.f6564.
4. Valdés G. Preeclampsia and cardiovascular disease: Interconnected paths that enable detection of the subclinical stages of obstetric and cardiovascular diseases. *Integr Blood Press Control*. 2017;10:17-23. doi:10.2147/IBPC.S138383.
5. Hauspurg A, Countouris ME, Jeyabalan A, et al. Risk of hypertension and abnormal biomarkers in the first year postpartum associated with hypertensive disorders of pregnancy among overweight and obese women. *Pregnancy Hypertens*. 2019;15:1-6. doi:10.1016/j.preghy.2018.10.009.
6. Tucker MJ, Berg CJ, Callaghan WM, Hsia J. The black-white disparity in pregnancy-related mortality from 5 conditions: Differences in prevalence and case-fatality rates. *Am J Public Health*. 2007;97(2):247-251. doi:10.2105/AJPH.2005.072975.
7. Shahul S, Tung A, Minhaj M, et al. Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia/eclampsia. *Hypertens Pregnancy*. 2015;34(4):506-515. doi:10.3109/10641955.2015.1090581.
8. Tanaka M, Jaamaa G, Kaiser M, et al. Racial disparity in hypertensive disorders of pregnancy in New York state: A 10-year longitudinal population-based study. *Am J Public Health*. 2007;97(1):163-170. doi:10.2105/AJPH.2005.068577.
9. Grobman WA, Parker CB, Willinger M, et al. Racial disparities in adverse pregnancy outcomes and psychosocial stress. *Obstet Gynecol*. 2018;131(2):328-335. doi:10.1097/AOG.0000000000002441.
10. Tanya Nagahawatte N, Goldenberg RL. Poverty, maternal health, and adverse pregnancy outcomes. *Ann N Y Acad Sci*. 2008;1136(1):80-85. doi:10.1196/annals.1425.016.
11. Sheen J-J, Huang Y, Wright JD, Goffman D, D'Alton ME, Friedman AM. 318: Maternal age and preeclampsia outcomes. *Am J Obstet Gynecol*. 2019;220(1):S222-S223. doi:10.1016/j.ajog.2018.11.339.
12. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet*. 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3.
13. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol*. 2013;14(10):R115. doi:10.1186/gb-2013-14-10-r115.
14. Hannum G, Guinney J, Zhao L, et al. Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. *Mol Cell*. 2013;49(2):359-367. doi:10.1016/j.molcel.2012.10.016.
15. Zhang Q, Vallerga CL, Walker RM, et al. Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing. *Genome Med*. 2019;11(1):54. doi:10.1186/s13073-019-0667-1.
16. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*. 2018;10(4):573-591. doi:10.18632/aging.101414.
17. Wang X, Zhu H, Snieder H, et al. Obesity related methylation changes in DNA of

DNA METHYLATION AGE ACROSS PREGNANCY

- peripheral blood leukocytes. *BMC Med.* 2010;8:87. doi:10.1186/1741-7015-8-87.
18. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics.* 2012;13(1):86. doi:10.1186/1471-2105-13-86.
19. Ray M, Heinsberg LW, Conley YP, et al. Utilization of Epigenome-wide DNA Methylation for Longitudinal Comparison of White Blood Cell Proportions Across Preeclamptic and Normotensive Pregnancy by Self-Reported Race. *medRxiv.* 2020. doi:10.1101/2020.09.18.20197491.
20. Zhang Q. DNA methylation based chronological age predictor. 2019. doi:10.5281/zenodo.3369456.
21. Team RC. R: A language and environment for statistical computing. 2018. <https://www.r-project.org/>.
22. Jolliffe IT, Cadima J. Principal component analysis: A review and recent developments. *Philos Trans R Soc A Math Phys Eng Sci.* 2016;374(2065):20150202. doi:10.1098/rsta.2015.0202.
23. El Khoury LY, Gorrie-Stone T, Smart M, et al. Systematic underestimation of the epigenetic clock and age acceleration in older subjects. *Genome Biol.* 2019;20(1):283. doi:10.1186/s13059-019-1810-4.
24. Hughes A, Smart M, Gorrie-Stone T, et al. Socioeconomic Position and DNA Methylation Age Acceleration Across the Life Course. *Am J Epidemiol.* 2018;187(11):2346-2354. doi:10.1093/aje/kwy155.
25. Kresovich JK, Taylor JA. RE: "SOCIOECONOMIC POSITION AND DNA METHYLATION AGE ACCELERATION ACROSS the LIFE COURSE." *Am J Epidemiol.* 2019;188(2):487-488. doi:10.1093/aje/kwy246.
26. Hughes A, Bao Y, Smart M, et al. THE AUTHORS REPLY. *Am J Epidemiol.* 2019;188(2):488-489. doi:10.1093/aje/kwy247.
27. Mayne BT, Leemaqz SY, Smith AK, Breen J, Roberts CT, Bianco-Miotto T. Accelerated placental aging in early onset preeclampsia pregnancies identified by DNA methylation. *Epigenomics.* 2017;9(3):279-289. doi:10.2217/epi-2016-0103.
28. Ross KM, Carroll J, Horvath S, Hobel CJ, Coussons-Read ME, Dunkel Schetter C. Immune epigenetic age in pregnancy and 1 year after birth: Associations with weight change. *Am J Reprod Immunol.* 2020;83(5). doi:10.1111/aji.13229.
29. Ross KM, Carroll JE, Horvath S, Hobel CJ, Coussons-Read ME, Dunkel Schetter C. Epigenetic age and pregnancy outcomes: GrimAge acceleration is associated with shorter gestational length and lower birthweight. *Clin Epigenetics.* 2020;12(1):120. doi:10.1186/s13148-020-00909-2.
30. Hunt SC, Chen W, Gardner JP, et al. Leukocyte telomeres are longer in African Americans than in whites: The National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. *Aging Cell.* 2008;7(4):451-458. doi:10.1111/j.1474-9726.2008.00397.x.
31. Rewak M, Buka S, Prescott J, et al. Race-related health disparities and biological aging: Does rate of telomere shortening differ across blacks and whites? *Biol Psychol.* 2014;99(1):92-99. doi:10.1016/j.biopsycho.2014.03.007.
32. Horvath S, Gurven M, Levine ME, et al. An epigenetic clock analysis of race/ethnicity, sex, and coronary heart disease. *Genome Biol.* 2016;17(1):171. doi:10.1186/s13059-016-1030-0.

DNA METHYLATION AGE ACROSS PREGNANCY

33. Li C, Wang Z, Hardy T, et al. Association of obesity with DNA methylation age acceleration in african American mothers from the interGEN study. *Int J Mol Sci*. 2019;20(17). doi:10.3390/ijms20174273.
34. De Toro-Martín J, Guénard F, Tchernof A, et al. Body mass index is associated with epigenetic age acceleration in the visceral adipose tissue of subjects with severe obesity. *Clin Epigenetics*. 2019;11(1):172. doi:10.1186/s13148-019-0754-6.
35. Harmon AC, Cornelius DC, Amaral LM, et al. The role of inflammation in the pathology of preeclampsia. *Clin Sci (Lond)*. 2016;130(6):409-419. doi:10.1042/CS20150702.
36. Konkel L. Racial and ethnic disparities in research studies: The challenge of creating more diverse cohorts. *Environ Health Perspect*. 2015;123(12):A297-A302. doi:10.1289/ehp.123-A297.
37. Lim EM, Cembrowski G, Cembrowski M, Clarke G. Race-specific WBC and neutrophil count reference intervals. *Int J Lab Hematol*. 2010;32(6 PART 2):590-597. doi:10.1111/j.1751-553X.2010.01223.x.

DNA METHYLATION AGE ACROSS PREGNANCY

Table 1. Demographic and clinical characteristics by PE status and self-reported race.

Variable	PE status			Self-Reported Race		
	Preeclampsia Cases (n = 28)	Normotensive Controls (n = 28)	<i>p</i>	Black (n = 42)	White (n = 14)	<i>p</i>
Chronological Age, mean years (SD)	23.9 (5.0)	23.7 (4.2)	0.82 ^a	22.2 (3.1)	28.4 (5.2)	0.0007 ^a
PE Status, n (%)	NA			21 (75.0)	21 (75.0)	1 ^b
<i>Case (PE+)</i>				7 (25.0)	7 (25.0)	
<i>Control (PE-)</i>				NA		
Self-Reported Race, n (%)	1 ^b			21 (75.0)	21 (75.0)	0.06 ^a
<i>Black</i>				7 (25.0)	7 (25.0)	
<i>White</i>				NA		
Pre-pregnancy BMI, mean kg/m ² (SD)	33.0 (5.0)	33.7 (4.2)	0.73 ^a	32.3 (7.5)	36.5 (6.6)	0.06 ^a
>100 Lifetime Cigarettes, n (%)	0.78 ^b			29 (69.0)	8 (57.1)	0.42 ^b
<i>No</i>				13 (31.0)	6 (42.9)	
<i>Yes</i>						
Marital Status, n (%)	1 ^b			31 (73.8)	3 (21.4)	0.0005 ^c
<i>Never Married</i>				11 (26.2)	11 (78.6)	
<i>Married or living in a marriage-like relationship</i>						
Education, n (%)	0.97 ^c			5 (11.9)	3 (21.4)	0.02 ^c
<i>< High school or diploma certificate</i>				19 (45.2)	3 (21.4)	
<i>High school or diploma certificate</i>				18 (42.9)	5 (35.8)	
<i>Some college, Vocational/technical, or Associate's degree</i>				0	3 (21.4)	
Household Income, n (%)	0.88 ^{c, d}			18 (42.9)	1 (7.1)	0.001 ^{c, d}
<i><\$10,000</i>				10 (23.8)	9 (64.3)	
<i>\$10,000 to \$34,999</i>				1 (2.4)	1 (7.1)	
<i>\$35,000 to \$49,999</i>				0	2 (14.4)	
<i>>\$50,000^e</i>						

DNA METHYLATION AGE ACROSS PREGNANCY

<i>Unknown^d</i>	8 (28.6)	6 (21.6)		13 (29.9)	1 (7.1)	
Public Assistance, n (%)						
<i>Yes</i>	14 (50.0)	14 (50.0)	1 ^b	22 (52.4)	6 (42.9)	0.54 ^b
<i>No</i>	14 (50.0)	14 (50.0)		20 (47.6)	8 (57.1)	
Gestational age at biosample collection ^f , mean weeks (SD)						
<i>Trimester 1</i>	8.7 (1.7)	8.8 (1.6)	0.87 ^a	8.8 (1.7)	8.7 (1.4)	0.96 ^a
<i>Trimester 2</i>	19.8 (1.7)	19.6 (0.8)	0.68 ^a	19.7 (1.3)	19.6 (1.1)	0.65 ^a
<i>Trimester 3</i>	37.0 (2.5)	37.4 (2.5)	0.58 ^a	37.0 (2.3)	37.9 (2.8)	0.32 ^a
Gestational age at delivery, mean weeks (SD)	37.4 (2.5)	39.5 (1.3)	0.0002 ^a	38.4 (2.1)	38.5 (2.6)	0.91 ^a
Infant birth weight, mean grams (SD)	2797.9 (732.8)	3385.6 (540.8)	0.001 ^a	3045.4 (695.9)	3230.9 (734.6)	0.42 ^a
Parity, n (%)						
<i>Nulliparous</i>	21 (75.0)	24 (85.7)	0.47 ^c	35 (83.3)	10 (71.4)	0.44 ^c
<i>Multiparous^g</i>	7 (25.0)	5 (14.3)		7 (16.7)	4 (28.6)	
Gravidity, mean number of pregnancies (SD)	1.9 (1.2)	1.9 (1.6)	1 ^a	1.6 (1.1)	2.5 (2.0)	0.15 ^a
Blood pressure <20 weeks, mean mmHg (SD)						
<i>Systolic</i>	112.8 (7.3)	111.5 (8.9)	0.57 ^a	110.6 (8.2)	116.8 (5.7)	0.004 ^a
<i>Diastolic</i>	70.1 (6.0)	66.8 (6.1)	0.05 ^a	68.1 (6.6)	69.5 (4.9)	0.41 ^a
Blood pressure upon hospital admission for delivery, mean mmHg (SD)						
<i>Systolic</i>	148.3 (6.9)	90.5 (8.1)	< 2.2E-16 ^a	136.5 (14.3)	136.3 (11.8)	0.97 ^a
<i>Diastolic</i>	124.5 (6.1)	71.1 (6.2)	1.10E-13 ^a	80.6 (12.8)	81.4 (10.4)	0.83 ^a

PE, preeclampsia; SD, standard deviation; ^aT-test; ^bChi-square test; ^cFisher's exact test; ^dParticipants with an unknown annual household income were excluded from formal analysis reported here; ^eOne extreme outlier reporting an annual household income >\$150,000 included in this income categorization; ^fGestational age at sample collection ranges included 5 to 13 weeks' (Trimester 1), 18 to 24 weeks' (Trimester 2), and 30 to 40 weeks' (Trimester 3); ^gMultiparous range of 1 to 3 pregnancies.

DNA METHYLATION AGE ACROSS PREGNANCY

Table 2. Results of multiple linear regression of examining associations between PE status and Δage while controlling for covariates.

Table 2A. Model unadjusted for cell-type heterogeneity									
	Δage , Trimester 1 (n=50)			Δage , Trimester 2 (n=53)			Δage , Trimester 3 (n=53)		
	β	95% CI	<i>p</i>	β	95% CI	<i>p</i>	β	95% CI	<i>p</i>
Intercept	-5.98	-26.81 to 14.96	0.57	3.96	-14.67 to 22.60	0.67	-4.33	-25.13 to 16.46	0.68
PE status									
<i>Case</i>	0.09	-1.35 to 1.53	0.90	-0.45	-1.66 to 0.76	0.46	-0.65	-2.03 to 0.73	0.35
<i>Control</i>		Reference			Reference			Reference	
Race									
<i>Black</i>	-1.37	-3.33 to 0.60	0.17	-2.68	-4.43 to -0.94	0.003	-2.10	-4.03 to -0.17	0.03
<i>White</i>		Reference			Reference			Reference	
Chronological age	0.02	-1.58 to 1.62	0.98	-0.45	-1.88 to 0.98	0.53	0.34	-1.27 to 1.94	0.67
(Chronological age) ²	0.0001	-0.03 to 0.03	0.99	0.01	-0.02 to 0.03	0.51	-0.01	-0.03 to 0.02	0.73
Pre-pregnancy BMI	0.12	0.02 to 0.22	0.02	0.05	-0.04 to 0.13	0.28	-0.02	-0.13 to 0.08	0.63
Table 2B. Model adjusted for cell-type heterogeneity									
	Δage , Trimester 1 (n=50)			Δage , Trimester 2 (n=53)			Δage , Trimester 3 (n=53)		
	β	95% CI	<i>p</i>	β	95% CI	<i>p</i>	β	95% CI	<i>p</i>
Intercept	-6.91	-28.78 to 14.95	0.53	4.20	-13.63 to 22.02	0.64	-1.37	-22.03 to 19.30	0.89
PE status									
<i>Case</i>	0.07	-1.47 to 1.61	0.93	-0.73	-1.90 to 0.44	0.21	-0.61	-1.98 to 0.76	0.37
<i>Control</i>		Reference			Reference			Reference	
Race									
<i>Black</i>	-1.37	-3.50 to 0.76	0.20	-2.82	-4.63 to -1.01	0.003	-1.34	-3.41 to 0.73	0.20
<i>White</i>		Reference			Reference			Reference	
Chronological age	0.08	-1.59 to 1.76	0.92	-0.53	-1.89 to 0.83	0.44	-0.03	-1.65 to 1.59	0.97
(Chronological age) ²	-0.001	-0.03 to 0.03	0.94	0.01	-0.02 to 0.03	0.46	0.001	-0.03 to 0.03	0.94
Pre-pregnancy BMI	0.13	0.02 to 0.24	0.03	0.09	-0.001 to 0.18	0.05	0.01	-0.01 to 0.12	0.86
Cell-type heterogeneity									
<i>PCI</i>	-0.06	-0.49 to 0.37	0.80	0.11	-0.26 to 0.49	0.55	0.30	-0.12 to 0.72	0.16

DNA METHYLATION AGE ACROSS PREGNANCY

<i>PC2</i>	-0.07	-1.10 to 0.97	0.89	-0.60	-1.36 to 0.15	0.12	0.32	-0.49 to 1.13	0.43
<i>PC3</i>	-0.26	-1.35 to 0.82	0.63	-1.02	-1.98 to -0.07	0.04	-0.92	-1.94 to 0.09	0.07

PE, preeclampsia; Δage =DNA methylation age – chronological age (Equation S1); PC, principal component; β , unstandardized regression coefficient; CI, confidence interval; R^2 values for model presented in Table 2A (Unadjusted for cell-type heterogeneity): 23.1% (Trimester 1), 30.1% (Trimester 2), and 19.2% (Trimester 3); R^2 values for model presented in Table 2B (Adjusted for cell-type heterogeneity): 23.8% (Trimester 1), 40.9% (Trimester 2), and 27.3% (Trimester 3).